These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 11851638)

  • 1. Dose-effect relationship for several coagulation markers during administration of the direct thrombin inhibitor S 18326 in healthy subjects.
    Gaussem P; Dubar M; le Bonniec B; Richard-Lordereau I; Jochemsen R; Aiach M
    Br J Clin Pharmacol; 2002 Feb; 53(2):147-54. PubMed ID: 11851638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
    Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
    Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
    Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
    Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
    Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK
    Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease.
    Cullberg M; Eriksson UG; Larsson M; Karlsson MO
    Br J Clin Pharmacol; 2001 Jan; 51(1):71-9. PubMed ID: 11167667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing.
    Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
    Ann Pharmacother; 2004 Sep; 38(9):1383-8. PubMed ID: 15238620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Hawes EM; Deal AM; Funk-Adcock D; Gosselin R; Jeanneret C; Cook AM; Taylor JM; Whinna HC; Winkler AM; Moll S
    J Thromb Haemost; 2013 Aug; 11(8):1493-502. PubMed ID: 23718677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulant activity of a peptide boronic acid thrombin inhibitor by various routes of administration in rats.
    Hussain MA; Knabb R; Aungst BJ; Kettner C
    Peptides; 1991; 12(5):1153-4. PubMed ID: 1800952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.
    Rupin A; Mennecier P; Lila C; de Nanteuil G; Verbeuren TJ
    Thromb Haemost; 1997 Oct; 78(4):1221-7. PubMed ID: 9364988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory assays for the evaluation of recombinant hirudin.
    Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
    Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
    Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
    Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization.
    Chen D; Långström S; Petäjä J; Heikinheimo M; Pihkala J
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1174-9. PubMed ID: 22915548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis.
    Liesenfeld KH; Schäfer HG; Trocóniz IF; Tillmann C; Eriksson BI; Stangier J
    Br J Clin Pharmacol; 2006 Nov; 62(5):527-37. PubMed ID: 17061960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
    Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
    Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.
    Samama MM; Mendell J; Guinet C; Le Flem L; Kunitada S
    Thromb Res; 2012 Apr; 129(4):e77-82. PubMed ID: 21851967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637.
    Deinum J; Mattsson C; Inghardt T; Elg M
    Thromb Haemost; 2009 Jun; 101(6):1051-9. PubMed ID: 19492147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor.
    Paccaly A; Ozoux ML; Chu V; Simcox K; Marks V; Freyburger G; Sibille M; Shukla U
    Thromb Haemost; 2005 Dec; 94(6):1156-63. PubMed ID: 16411387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crossover dose escalation study to assess safety, pharmacokinetics, and pharmacodynamics of single doses of R1663, an oral factor Xa inhibitor, in healthy male volunteers.
    Schmitt C; Pannier A; McIntyre C; Zandt H; Ciorciaro C; Winters K; Pepper T
    J Clin Pharmacol; 2012 Apr; 52(4):499-510. PubMed ID: 21566199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
    Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
    Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.